Genetic Background of Catecholaminergic Polymorphic Ventricular Tachycardia in Japan
Authors:
Open Access
- 1 January 2013
- journal article
- clinical trial
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 77 (7) , 1705-1713
Abstract
Background: The genetic background of catecholaminergic polymorphic ventricular tachycardia (CPVT) has been extensively investigated for the last decade in Western countries, but it remains unstudied in the Asian population. Methods and Results: In 50 Japanese probands from unrelated families who satisfied clinical criteria for CPVT, genetic testing was conducted in all exons on 3 CPVT-related genes: cardiac ryanodine receptor 2 (RYR2), calsequestrin 2 (CASQ2) and inward rectifier potassium channel 2 (KCNJ2), and the clinical features between RYR2-genotyped and -non-genotyped patient groups were compared. Genetic and clinical evaluation was also done in 46 family members. In the genetic screening, 28 (18 novel) RYR2 (56.0%), 1 compound heterozygous CASQ2 (2.0%) and 1 KCNJ2 (2.0%) mutation carriers were identified. In the RYR2 mutation-positive group, the frequency of bidirectional ventricular tachycardia and the use of β-blockers were significantly higher than in the mutation-negative group. In contrast, there was no significant difference in supraventricular arrhythmias between the 2 groups. With regard to disease penetrance, the number of family members of RYR2-genotyped probands with a clinical diagnosis of CPVT was high. Conclusions: Thirty gene mutation carriers were found for 3 genes in 50 probands clinically diagnosed as having CPVT. The penetrance of CPVT phenotype was significantly higher in RYR2 mutation carriers, thus RYR2 gene screening in CPVT patients would be indispensable to prevent unexpected cardiac sudden death of young family members. (Circ J 2013; 77: 1705–1713)Keywords
This publication has 34 references indexed in Scilit:
- Familial Evaluation in Catecholaminergic Polymorphic Ventricular TachycardiaCirculation: Arrhythmia and Electrophysiology, 2012
- Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in humanHuman Molecular Genetics, 2012
- Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular TachycardiaJACC, 2011
- Possible Targets of Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia - Insight From a Theoretical Model -Circulation Journal, 2011
- The RYR2-Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT SyndromeJACC, 2009
- Protein Kinase A-Dependent Biophysical Phenotype for V227F-KCNJ2 Mutation in Catecholaminergic Polymorphic Ventricular TachycardiaCirculation: Arrhythmia and Electrophysiology, 2009
- Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humansNature Medicine, 2009
- A Novel Early Onset Lethal Form of Catecholaminergic Polymorphic Ventricular Tachycardia Maps to Chromosome 7p14‐p22Journal of Cardiovascular Electrophysiology, 2007
- Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testingHeart Rhythm, 2006
- A novel mutation (Arg169Gln) of the cardiac ryanodine receptor gene causing exercise-induced bidirectional ventricular tachycardiaInternational Journal of Cardiology, 2006